MX2007014428A - Metodo para reducir la sepsis o el choque cardiogenico asociado a una lesion del miocardio. - Google Patents

Metodo para reducir la sepsis o el choque cardiogenico asociado a una lesion del miocardio.

Info

Publication number
MX2007014428A
MX2007014428A MX2007014428A MX2007014428A MX2007014428A MX 2007014428 A MX2007014428 A MX 2007014428A MX 2007014428 A MX2007014428 A MX 2007014428A MX 2007014428 A MX2007014428 A MX 2007014428A MX 2007014428 A MX2007014428 A MX 2007014428A
Authority
MX
Mexico
Prior art keywords
sepsis
cardiogenic shock
reducing
myocardial injury
shock associated
Prior art date
Application number
MX2007014428A
Other languages
English (en)
Inventor
Thomas Gerald Todaro
Kevin John Malloy
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MX2007014428A publication Critical patent/MX2007014428A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen metodos para reducir la sepsis o el choque cardiogenico en pacientes que sufren una lesion del miocardio; mas especificamente, esta exposicion se refiere a la administracion de un inhibidor terminal de complementos C5-C9 a pacientes a los cuales se les ha realizado un injerto de derivacion de la arteria coronaria o que han sufrido un infarto agudo de miocardio reduciendo asi la incidencia de sepsis.
MX2007014428A 2005-05-19 2006-05-18 Metodo para reducir la sepsis o el choque cardiogenico asociado a una lesion del miocardio. MX2007014428A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68263805P 2005-05-19 2005-05-19
PCT/US2006/019622 WO2006125200A2 (en) 2005-05-19 2006-05-18 Method for reducing sepsis or cardiogenic shock associated with myocardial injury

Publications (1)

Publication Number Publication Date
MX2007014428A true MX2007014428A (es) 2008-04-21

Family

ID=37101919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007014428A MX2007014428A (es) 2005-05-19 2006-05-18 Metodo para reducir la sepsis o el choque cardiogenico asociado a una lesion del miocardio.

Country Status (4)

Country Link
US (1) US20060263358A1 (es)
CA (1) CA2609071A1 (es)
MX (1) MX2007014428A (es)
WO (1) WO2006125200A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2894165T (pt) * 2008-11-10 2023-03-17 Alexion Pharma Inc Métodos e composições para o tratamento de distúrbios associados ao complemento
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis

Also Published As

Publication number Publication date
WO2006125200A3 (en) 2007-01-25
WO2006125200A2 (en) 2006-11-23
US20060263358A1 (en) 2006-11-23
CA2609071A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
HK1258159A1 (zh) 脯氨醯羥化酶抑制劑及使用方法
NO20084253L (no) Tetrahydroisokinolinderivater for a forbedre hukommelsesfunksjon
WO2007026251A3 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
EP2338490A3 (en) Combinations useful for the treatment of neuronal disorders
WO2006060414A3 (en) Compositions and methods for the treatment of autism
EP1756074A4 (en) 1,2,4-OXADIAZOLE DERIVATIVES AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV IN THE TREATMENT OR PREVENTION OF DIABETES
WO2006020060A3 (en) Iap binding compounds
WO2007101225A3 (en) Methods to identify inhibitors of the unfolded protein response
HRP20110969T1 (en) Pimobendan to be used for the reduction of heart size in mammals suffering from heart failure
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
WO2006102061A3 (en) Methods of decreasing calcification
IL190730A0 (en) Potassium channel inhibitors
WO2007050348A3 (en) Potassium channel inhibitors
WO2009082134A3 (en) Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
WO2008085229A3 (en) Cell-based therapies for treating liver disease
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
ATE505955T1 (de) Kaffeezusammensetzung
WO2002016416A3 (en) Diagnosis and treatment of cardiovascular conditions
WO2007112015A3 (en) Phenolic hydrazone macrophage migration inhibitory factor inhibitors
WO2010005565A3 (en) Method of treating glycogen storage disease
WO2004087066A3 (en) Hif-1 inhibitors
WO2007100765A3 (en) Lysozyme-modified probiotic components and uses thereof
MX2007014428A (es) Metodo para reducir la sepsis o el choque cardiogenico asociado a una lesion del miocardio.
WO2005094602A3 (en) Purified extract of an alpha-amylase inhibitor from phytoemagglutinin-essentially free beans, process for its extraction and compositions containing it
WO2005030792A3 (en) Quinoline potassium channel inhibitors